Substance / Medication

Turoctocog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
Drillaud Nicolas, Cussac Vincent, Bertho Pierre-Olivier et al. · Transfusion · 2023
PMID: 37850587Observational
Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).
Klamroth Robert, Hampton Kingsley, Saulyte Trakymienė Sonata et al. · Patient Prefer Adherence · 2021
PMID: 34764641Case ReportFull text (PMC)
Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
Takeyama Masahiro, Nogami Keiji, Kobayashi Ryohei et al. · Int J Hematol · 2018
PMID: 29383626Case Report
Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient.
Feistritzer Clemens, Wildner Sophie Maria, Würtinger Philipp et al. · Blood Coagul Fibrinolysis · 2017
PMID: 27152926Case Report
Turoctocog alfa pegol versus recombinant factor VIII-Fc fusion protein: a head-to-head pharmacokinetics comparison.
Poz Alessandra, Contino Laura, Barillari Giovanni · Blood Transfus · 2025
PMID: 40901794Other
Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal.
Ay Cihan, Benitez-Hidalgo Olga, Gidley Gillian et al. · Res Pract Thromb Haemost · 2024
PMID: 38572481OtherFull text (PMC)
The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
Male Christoph, Königs Christoph, Dey Sohan et al. · Blood Adv · 2023
PMID: 35858373TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Turoctocog alfa (substance)
SNOMED CT
735055007
UMLS CUI
C3529563

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.